Alcestobart clinical trials
Also written LBL-007.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses alcestobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Tislelizumab (3) · Surzebiclimab (1) · Toripalimab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses alcestobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerActive, not recruitingPhase 1/2BeiGeneNCT05609370Written as Alcestobart
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedPhase 2BeiGeneNCT06010303Written as LBL-007
- A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced MelanomaCompletedPhase 1Nanjing Leads Biolabs Co.,LtdNCT04640545Written as LBL-007
- Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid TumorsCompletedPhase 1/2BeiGeneNCT03744468Written as Alcestobart
- A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant TumorsCompletedPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT05516914Written as LBL-007 Injection
- A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant TumorsCompletedPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT05102006Written as LBL-007 Injection
Given beside what is tested · 4 — alcestobart is usual care or a partner of the new treatment
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedPhase 2BeiGeneNCT05635708Written as LBL-007
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaCompletedPhase 2BeiGeneNCT05909904Written as LBL-007
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as LBL-007
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerCompletedPhase 2BeiGeneNCT05577702Written as Alcestobart
Codes
What other systems call alcestobart · ClinicalTrials.gg INT018067
- UNII (FDA) U1GA9GN97DALCESTOBARTOne source FDA
- NCI Thesaurus C179260AlcestobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U1GA9GN97D | ALCESTOBART | One source FDA |
| NCI Thesaurus | C179260 | Alcestobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.